Liver transplantation meets gastrointestinal cancer

Sven H. Loosen; Catherine Leyh; Ulf Peter Neumann; Hans Bock; Christian Weigel; Tom Luedde; Christoph Roderburg

doi:10.1055/a-2226-0123

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2024; 62(01): 62-72
DOI: 10.1055/a-2226-0123

Übersicht

Liver transplantation meets gastrointestinal cancer

Lebertransplantation bei gastrointestinalen Tumoren

Sven H. Loosen

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

,

Catherine Leyh

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

,

Ulf Peter Neumann

³Department of General, Visceral and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, Germany

⁴Department of Surgery and Transplantation, University Hospital Essen, Essen, Germany

,

Hans Bock

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

,

Christian Weigel

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

,

Tom Luedde

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

,

Christoph Roderburg

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN39064)

²Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany

› Author Affiliations

Abstract

Liver transplantation (LT) has emerged as a standard of care for patients with end-stage liver disease, providing a life-saving intervention for patients with severely compromised liver function in both the acute and chronic setting. While LT has also become a routine procedure for early-stage hepatocellular carcinoma (HCC), offering a potential cure by treating both the tumor and the underlying liver disease, its relevance in the context of other malignancies such as cholangiocellular carcinoma (CCA), combined hepatocellular-cholangiocarcinoma (cHCC-CCA) or liver metastases is still the subject of intense debate and no definite recommendations have yet been established. This review summarizes the current therapeutic standards in the context of LT for gastrointestinal malignancies and provides a reflection and outlook on current scientific and clinical developments.

Zusammenfassung

Die Lebertransplantation (LT) hat sich als Standardbehandlung für Patienten mit Lebererkrankungen im Endstadium etabliert und stellt sowohl im akuten als auch im chronischen Stadium einen lebensrettenden Eingriff für Patienten mit stark eingeschränkter Leberfunktion dar. Während die Lebertransplantation auch für das hepatozelluläre Karzinom (HCC) im Frühstadium zu einem Routineverfahren geworden ist und eine potenzielle Heilung bietet, indem sowohl der Tumor als auch die zugrunde liegende Lebererkrankung behandelt werden, wird ihre Relevanz im Zusammenhang mit anderen bösartigen Erkrankungen wie dem cholangiozellulären Karzinom (CCA), dem kombinierten hepatozellulären/cholangiozellulären Karzinom (cHCC-CCA) oder Lebermetastasen noch immer intensiv diskutiert, und es gibt noch keine definitiven Empfehlungen. Diese Übersicht fasst die aktuellen Therapiestandards im Rahmen der LT bei gastrointestinalen Malignomen zusammen und gibt einen Überblick über und Ausblick auf die aktuellen wissenschaftlichen und klinischen Entwicklungen.

Keywords

HCC - CCA - cHCC/CCA - MELD - Eurotransplant - liver transplantation

Schlüsselwörter

HCC - CCC - cHCC/CCC - MELD - Eurotransplant - Lebertransplantation

Full Text

References

References
1 Kwong AJ, Kim WR, Lake JR. et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant 2021; 21: 208-315
2 Durand F. How to improve long-term outcome after liver transplantation?. Liver Int 2018; 38: 134-138
3 Adam R, Karam V, Cailliez V. et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293-1317
4 Lang SA, Bednarsch J, Czigany Z. et al. Liver transplantation in malignant disease. WJCO 2021; 12: 623-645
5 Loosen SH, Bock HH, Hellmich M. et al. Hospital Mortality and Current Trends in Liver Transplantation in Germany—a Systematic Analysis of Standardized Hospital Discharge Data, 2008–2017. Dtsch Arztebl Int 2021; 118: 497-502
6 Hibi T, Sapisochin G. What is transplant oncology?. Surgery 2019; 165: 281-285
7 Yang JD, Hainaut P, Gores GJ. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16: 589-604
8 Bednarsch J, Czigany Z, Heise D. et al. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg 2021; 406: 75-86
9 Menahem B, Lubrano J, Duvoux C. et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl 2017; 23: 836-844
10 Proneth A, Zeman F, Schlitt HJ. et al. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 2014; 21: 3096-3107
11 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
12 Bento de Sousa JH, Calil IL, Tustumi F. et al. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol 2021; 6: 11
13 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43
14 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
15 Hameed B, Mehta N, Sapisochin G. et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-951
16 Shimamura T, Akamatsu N, Fujiyoshi M. et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5–5-500 rule – a retrospective study. Transpl Int 2019; 32: 356-368
17 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154: 128-139
18 Cucchetti A, Serenari M, Sposito C. et al. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol 2020; 73: 342-348
19 Firl DJ, Sasaki K, Agopian VG. et al. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2020; 71: 569-582
20 Sasaki K, Firl DJ, Hashimoto K. et al. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol 2017; 2: 595-603
21 Goldberg D, Mantero A, Newcomb C. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol 2021; 74: 1398-1406
22 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol 2021; 9: 220-226
23 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
24 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400
25 Miller CM, Quintini C, Dhawan A. et al. The International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline. Transplantation 2017; 101: 938-944
26 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
27 Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310-312
28 Herrero JI, Sangro B, Pardo F. et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-278
29 Silva M, Moya A, Berenguer M. et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460
30 Toso C, Meeberg G, Hernandez-Alejandro R. et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015; 62: 158-165
31 Kaido T, Ogawa K, Mori A. et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154: 1053-1060
32 Shirabe K, Taketomi A, Morita K. et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant 2011; 25: E491-498
33 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152
34 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977
35 Mazzaferro V, Citterio D, Bhoori S. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21: 947-956
36 Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020; 11: 3801
37 Ruff SM, Manne A, Cloyd JM. et al. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Curr Oncol 2023; 30: 5863-5875
38 Cheng A-L, Qin S, Ikeda M. et al. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of Oncology 2019; 30: ix186-ix187
39 Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence 2022; 1
40 Pinato DJ, Fessas P, Sapisochin G. et al. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology 2021; 74: 483-490
41 Nordness MF, Hamel S, Godfrey CM. et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. Am J Transplant 2020; 20: 879-883
42 Chen G-H, Wang G-B, Huang F. et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol 2021; 66: 101386
43 Grigg SE, Sarri GL, Gow PJ. et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2019; 49: 1260-1273
44 Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC. et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199
45 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100: 116-125
46 Schnitzbauer AA, Filmann N, Adam R. et al. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Ann Surg 2020; 272: 855-862
47 Bzeizi KI, Smith R, Albenmousa A. et al. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Transplant Proc 2021; 53: 148-158
48 Mazzaferro V, Gorgen A, Roayaie S. et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020; 72: 364-377
49 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122
50 Goldstein RM, Stone M, Tillery GW. et al. Is liver transplantation indicated for cholangiocarcinoma?. Am J Surg 1993; 166: 768-771
51 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al. Liver transplantation for „very early“ intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64: 1178-1188
52 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259: 944-952
53 Vilchez V, Shah MB, Daily MF. et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18: 29-34
54 Facciuto ME, Singh MK, Lubezky N. et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation 2015; 99: 151-157
55 Lunsford KE, Javle M, Heyne K. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3: 337-348
56 McMillan RR, Javle M, Kodali S. et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 2022; 22: 823-832
57 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637
58 Shimoda M, Farmer DG, Colquhoun SD. et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001; 7: 1023-1033
59 Robles R, Figueras J, Turrión VS. et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239: 265-271
60 Brandsaeter B, Isoniemi H, Broomé U. et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-822
61 Tan EK, Taner T, Heimbach JK. et al. Liver Transplantation for Peri-hilar Cholangiocarcinoma. J Gastrointest Surg 2020; 24: 2679-2685
62 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010; 23: 692-697
63 Breuer E, Mueller M, Doyle MB. et al. Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study. Ann Surg 2022; 276: 846-853
64 Cambridge WA, Fairfield C, Powell JJ. et al. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Ann Surg 2021; 273: 240-250
65 Ethun CG, Lopez-Aguiar AG, Anderson DJ. et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg 2018; 267: 797-805
66 Rosen CB. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Paradigms for Resectable Disease in Annals of Surgery 2018. Ann Surg 2018; 267: 808-809
67 Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma 2019; 6: 11-21
68 Garancini M, Goffredo P, Pagni F. et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014; 20: 952-959
69 Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol 2013; 107: 608-612
70 Park Y-H, Hwang S, Ahn C-S. et al. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc 2013; 45: 3038-3040
71 Sapisochin G, Javle M, Lerut J. et al. Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1125-1130
72 Jung D-H, Hwang S, Song G-W. et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. Liver Transpl 2017; 23: 330-341
73 Li D-B, Si X-Y, Wang S-J. et al. Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int 2019; 18: 12-18
74 Dageforde LA, Vachharajani N, Tabrizian P. et al. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. J Am Coll Surg 2021; 232: 361-371
75 Ito T, Ishii T, Sumiyoshi S. et al. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: A case series of four patients. Int J Surg Case Rep 2020; 74: 46-52
76 Claasen MPAW, Ivanics T, Beumer BR. et al. An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma✰. JHEP Rep 2023; 5: 100745
77 Mühlbacher F, Huk I, Steininger R. et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver?. Transplant Proc 1991; 23: 1567-1568
78 Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110: 726-734
79 Pichlmayr R, Weimann A, Tusch G. et al. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist 1997; 2: 164-170
80 Frilling A, Modlin IM, Kidd M. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15: e8-e21
81 Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I. et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery 2017; 162: 525-536
82 Le Treut YP, Grégoire E, Klempnauer J. et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257: 807-815
83 Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?. J Hepatol 2007; 47: 460-466
84 Mazzaferro V, Sposito C, Coppa J. et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant 2016; 16: 2892-2902
85 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol 2020; 11: 601-608
86 Hagness M, Foss A, Line P-D. et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257: 800-806
87 Dueland S, Syversveen T, Solheim JM. et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Annals of Surgery 2020; 271: 212-218
88 Giannis D, Sideris G, Kakos CD. et al. The role of liver transplantation for colorectal liver metastases: A systematic review and pooled analysis. Transplant Rev (Orlando) 2020; 34: 100570
89 Hibi T, Rela M, Eason JD. et al. Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1131-1135
90 Lau K, Massad M, Pollak C. et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011; 140: 1312-1318
91 Lerut JP, Orlando G, Adam R. et al. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg 2007; 246: 949-957
92 Lai Q, Feys E, Karam V. et al. Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Transplantation 2017; 101: 555-564
93 Mehrabi A, Kashfi A, Fonouni H. et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107: 2108-2121